Valuation: FunPep Company Limited

Market Cap 2.53B 15.46M 13.59M 12.68M 11.64M 21.79M 1.48B 22.32M 150M 58.81M 733M 58.05M 56.79M P/E 2024
-4.22x
P/E 2025 -1.63x
Enterprise Value 765M 4.67M 4.1M 3.83M 3.52M 6.58M 447M 6.74M 45.43M 17.77M 221M 17.54M 17.16M EV / Sales 2024
338x
EV / Sales 2025 -
Free-Float
79.81%
Yield 2024 *
-
Yield 2025 -
03-08 FunPep Company Limited announced that it has received ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
02-19 FunPep Company Limited announced that it expects to receive ¥32.5315 million in funding from Next Growth Co., Ltd., Growth Capital, Inc. CI
09/03/25 FunPep Company Limited announced that it has received ¥3.6 million in funding from SBI Securities Co., Ltd. CI
20/02/25 FunPep Company Limited announced that it expects to receive ¥3.6 million in funding from SBI Securities Co., Ltd. CI
21/07/24 FunPep Company Limited announced that it has received ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
04/07/24 FunPep Company Limited announced that it expects to receive ¥3.52 million in funding from SBI SECURITIES Co., Ltd. CI
20/03/24 FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
03/03/24 FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
14/11/23 FunPep Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
15/05/23 FunPep Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
30/09/22 FunPep Company Limited completed the acquisition of Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
13/07/22 FunPep Company Limited agreed to acquire Anti-Aging Peptide Co., Ltd. from Hironori Nakagami , Bio Site Start Fund L.P., Naotaka Hashiya, Chiyako Ueda, ReBeage Co., Ltd. and others. CI
12/12/21 FunPep Company Limited announced that it has received ¥3.741 million in funding from SBI Securities Co., Ltd., Investment Arm CI
1 day-3.85%
1 week-26.47%
Current month-18.03%
1 month-15.25%
3 months-28.57%
6 months-42.53%
Current year-39.02%
1 week 50
Extreme 50
68
1 month 50
Extreme 50
76
Current year 50
Extreme 50
130
1 year 50
Extreme 50
130
3 years 50
Extreme 50
325
5 years 50
Extreme 50
477
10 years 50
Extreme 50
843
Manager TitleAgeSince
Director of Finance/CFO 53 30/04/2015
President 62 31/12/2019
Chief Tech/Sci/R&D Officer 54 30/06/2015
Director TitleAgeSince
Chairman 78 28/02/2015
Director/Board Member 62 28/02/2015
Director/Board Member 54 30/11/2015
Date Insider Type Main position Quantity % Market Cap.
28/04/25
Sola KK
OthersCompany 40,000 0.1234%
28/04/25
Sola KK
OthersCompany 110,000 0.3394%
28/04/25 Others 40,000 0.1234%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-26.47%-54.13%-71.91% 16.09M
+2.61%+7.16%-0.93%+13.78% 47.88B
-1.24%-0.77%+390.76%+591.92% 39.09B
-1.07%+2.04%+6.77%+52.39% 36.75B
+0.95%+23.07%+25.58%+9.19% 40.55B
+1.47%+4.90%+6.48%+43.52% 27.96B
-0.54%+0.58% - - 16.77B
+1.22%+9.49%+29.09%+128.40% 15.94B
+0.18%-2.75%+3.22%+9.68% 13.55B
+0.49%+7.99%-2.47%-28.15% 13.81B
Average -0.04%+1.84%+44.93%+83.20% 25.23B
Weighted average by Cap. +0.42%+5.06%+72.89%+123.55%

Financials

2024 2025
Net sales 6M 36.62K 32.18K 30.03K 27.56K 51.6K 3.51M 52.87K 356K 139K 1.74M 137K 134K -
Net income -889M -5.43M -4.77M -4.45M -4.08M -7.64M -520M -7.83M -52.77M -20.64M -257M -20.37M -19.93M -1.91B -11.66M -10.25M -9.57M -8.78M -16.43M -1.12B -16.84M -113M -44.36M -553M -43.79M -42.84M
Net Debt -2.35B -14.32M -12.58M -11.74M -10.78M -20.17M -1.37B -20.67M -139M -54.46M -679M -53.76M -52.59M -1.77B -10.79M -9.48M -8.85M -8.12M -15.2M -1.03B -15.58M -105M -41.04M -511M -40.51M -39.63M
Logo FunPep Company Limited
FunPep Co Ltd is a Japan-based company engaged in the research and development business for pharmaceuticals. The main business is to promote research and development of functional peptides, which are the results of research at the Graduate School of Medicine, Osaka University, and to put them into practical use in the business fields such as pharmaceuticals, cosmetics and medical devices. The business model defines its technical area as a functional peptide-based area and a related area that has synergies with it. The Research & Development pipeline is composed of research themes for antibody-inducing peptides and developed products. The Company is engaged in the sale of peptide active ingredients through cosmetic raw material trading companies or sales companies.
Employees
15
Date Price Change Volume
29/07/26 JP¥50.00 -3.85% 769,900
28/07/26 JP¥52.00 -23.53% 2,875,400
27/07/26 JP¥68.00 +4.62% 105,600
24/07/26 JP¥65.00 -4.41% 158,500
23/07/26 JP¥68.00 +1.49% 70,300

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4881 Stock